) announced that the first patient has been dosed in a second
phase II study on candidate, OMS824.
Omeros is evaluating OMS824 for the treatment of patients with
symptomatic Huntington's disease (HD). OMS824 is Omeros' lead
candidate in its phosphodiesterase 10 (PDE10) program.
This phase II study will randomize patients to receive placebo
or one of three doses of OMS824. The study will evaluate the
tolerability, safety, pharmacokinetics of OMS824. The efficacy of
OMS824 will be assessed across three functional domains: motor,
cognitive and behavior. Omeros expects interim results in the
second half of 2014 and final results in 2015. We note that the
candidate enjoys Orphan Drug and Fast Track designation in the
U.S. for HD.
Last month, Omeros provided positive results from a phase IIa
study on OMS824, which is being evaluated for the treatment of
schizophrenia. The study demonstrated that OMS824 showed systemic
pharmacokinetics when administered alone and concurrently
with approved antipsychotic agents in schizophrenic patients. A
Fast Track application is also under review in the U.S. for
OMS824 for the treatment of schizophrenia.
We are encouraged by the pipeline progress at Omeros. Omeros'
most advanced and proprietary pharmacosurgery candidate is
Omidria. The company is looking to get Omidria approved in the
U.S. and EU for the treatment of patients undergoing intraocular
lens replacement surgery. Omeros expects to market Omidria in the
second half of 2014 on approval.
Omeros currently carries a Zacks Rank #3 (Hold). Investors
looking for better-ranked stocks in the biopharma sector may
consider companies like
Biogen Idec Inc.
). Endocyte and Biogen carry a Zacks Rank #1 (Strong Buy) while
Actelion carries a Zacks Rank #2 (Buy).
ACTELION LTD (ALIOF): Get Free Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
ENDOCYTE INC (ECYT): Free Stock Analysis
OMEROS CORP (OMER): Free Stock Analysis
To read this article on Zacks.com click here.